Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis

Cancer Medicine

Volumn 6, Issue 7, 2017, Pages 1738-1751

  Saraswat, Mayank ^a,b   Joenväärä, Sakari ^a,b   Seppänen, Hanna ^b   Mustonen, Harri ^b   Haglund, Caj ^b,c   Renkonen, Risto ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Chronic pancreatitis; HDMSE; OPLS DA; Pancreatic adenocarcinoma; Pancreatic cancer

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CADHERIN RELATED PROTEIN; INTER ALPHA TRYPSIN INHIBITOR; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H2; LIVER X RECEPTOR; PROTHROMBIN; PROTOCADHERIN ALPHA 13; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; PLASMA PROTEIN; PROTEOME; TUMOR MARKER;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER STAGING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; PANCREAS CANCER; PILOT STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DEPLETION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; COMPLICATION; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLISM; PANCREAS TUMOR; PROCEDURES; REPRODUCIBILITY; SIGNAL TRANSDUCTION; STATISTICAL MODEL;

BIOMARKERS, TUMOR; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MODELS, STATISTICAL; PANCREATIC NEOPLASMS; PANCREATITIS, CHRONIC; PROTEIN INTERACTION MAPPING; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SIGNAL TRANSDUCTION;

EID: 85020121861     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.1107     Document Type: Article

References (43)

1. Bedi, M. M. S., M. D. Gandhi, G. Jacob, V. Lekha, A. Venugopal, and H. Ramesh. 2009. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J. Gastroenterol. 28:24–27.
2. Koomen, J. M., L. N. Shih, K. R. Coombes, D. Li, L. C. Xiao, I. J. Fidler, et al. 2005. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin.Cancer Res. 11:1110–1118.
3. Hanas, J. S., J. R. Hocker, J. Y. Cheung, J. L. Larabee, M. R. Lerner, S. A. Lightfoot, et al. 2008. Biomarker identification in human pancreatic cancer sera. Pancreas 36:61–69.
4. Deng, R., Z. Lu, Y. Chen, L. Zhou, and X. Lu. 2007. Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34:310–317.
5. Ansari, D., R. Andersson, M. P. Bauden, B. Andersson, J. B. Connolly, C. Welinder, et al. 2015. Protein deep sequencing applied to biobank samples from patients with pancreatic cancer. J. Cancer Res. Clin. Oncol. 141:369–380.
6. Pan, S., R. Chen, D. A. Crispin, D. May, T. Stevens, M. McIntosh, et al. 2011. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J. Proteome Res. 10:2359–2376.
7. Saraswat, M., S. Joenväärä, T. Jain, A. K. Tomar, A. Sinha, S. Singh, et al. 2016. Human spermatozoa quantitative proteomic signature classifies normo- and asthenozoospermia. Mol. Cell Proteomics mcp.M116.061028.
8. Silva, J. C., M. V. Gorenstein, G.-Z. Li, J. P. C. Vissers, and S. J. Geromanos. 2006. Absolute quantification of proteins by LCMSE: a virtue of parallel ms acquisition. Mol. Cell Proteomics 5:144–156.
9. Serang, O., L. Moruz, M. R. Hoopmann, and L. Käll. 2012. Recognizing uncertainty increases robustness and reproducibility of mass spectrometry-based protein inferences. J. Proteome Res. 11:5586–5591.
10. Di Luca, A., M. Henry, P. Meleady, and R. O'Connor. 2015. Label-free LC-MS analysis of HER2 + breast cancer cell line response to HER2 inhibitor treatment. DARU 23:40.
11. Thévenot, E. A., A. Roux, Y. Xu, E. Ezan, and C. Junot. 2015. Analysis of the human adult urinary metabolome variations with age, body mass index, and gender by implementing a comprehensive workflow for univariate and opls statistical analyses. J. Proteome Res. 14:3322–3335.
12. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodol) 57:289–300.
13. Levin, Y., E. Hradetzky, and S. Bahn. 2011. Quantification of proteins using data-independent analysis (MSE) in simple andcomplex samples: a systematic evaluation. Proteomics 11:3273–3287.
14. Kamburov, A., R. Cavill, T. M. D. Ebbels, R. Herwig, and H. C. Keun. 2011. Integrated pathway-level analysis of transcriptomics and metabolomics data with IMPaLA. Bioinformatics 27:2917–2918.
15. Vizcaíno, J. A., A. Csordas, N. del-Toro, J. A. Dianes, J. Griss, I. Lavidas, et al. 2016. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 44:D447–D456.
16. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90.
17. Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11–30.
18. Homma, T., and R. Tsuchiya. 1991. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int. J.Pancreatol. 9:119–124.
19. Kim, J.-E., K. T. Lee, J. K. Lee, S. W. Paik, J. C. Rhee, and K. W. Choi. 2004. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J. Gastroenterol. Hepatol. 19:182–186.
20. Poruk, K. E., D. Z. Gay, K. Brown, J. D. Mulvihill, K. M. Boucher, C. L. Scaife, et al. 2013. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr. Mol. Med. 13:340–351.
21. Sun, B., A. G. Utleg, Z. Hu, S. Qin, A. Keller, C. Lorang, et al. 2013. Glycocapture-assisted global quantitative proteomics (gagQP) reveals multiorgan responses in serum toxicoproteome. J. Proteome Res. 12:2034–2044.
22. Hortin, G. L., and D. Sviridov. 2010. The dynamic range problem in the analysis of the plasma proteome. J. Proteomics. 73:629–636.
23. Bektas, M., S. G. Payne, H. Liu, S. Goparaju, S. Milstien, and S. Spiegel. 2005. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J. Cell Biol. 169:801–811.
24. Yu, K. H., A. K. Rustgi, and I. A. Blair. 2005. Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. J. Proteome Res. 4:1742–1751.
25. Munford, R. S., and J. Pugin. 2001. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am. J. Respir. Crit. Care Med. 163:316–321.
26. Ahmed, M. S., A. B. Jadhav, A. Hassan, and Q. H. Meng. 2012. Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm 2012:18.
27. Gruys, E., M. J. M. Toussaint, T. A. Niewold, and S. J. Koopmans. 2005. Acute phase reaction and acute phase proteins. J. Zhejiang Univ. Sci. B 6:1045–1056.
28. Salmiheimo, A., H. Mustonen, U.-H. Stenman, P. Puolakkainen, E. Kemppainen, H. Seppänen, et al. 2016. Systemic inflammatory response and elevated tumour markers predict worse survival in resectable pancreatic ductal adenocarcinoma. PLoS ONE 11:e0163064.
29. Kersten, C., J. Louhimo, A. Ålgars, A. Lahdesmaki, M. Cvancerova, K. Stenstedt, et al. 2013. Increased C-reactive protein implies a poorer stage-specific prognosis in colon cancer. Acta Oncol. 52:1691–1698.
30. Køstner, A. H., C. Kersten, T. Löwenmark, K. A. Ydsten, R. Peltonen, H. Isoniemi, et al. 2016. The prognostic role of systemic inflammation in patients undergoing resection of colorectal liver metastases: C-reactive protein (CRP) is a strong negative prognostic biomarker. J. Surg. Oncol. 114:895–899.
31. Delitto, D., E. Vertes-George, S. J. Hughes, K. E. Behrns, and J. G. Trevino. 2014. c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J. Gastroenterol. 20:8458–8470.
32. Matsushita, A., T. Götze, and M. Korc. 2007. Hepatocyte growth factor–mediated cell invasion in pancreatic cancer cells is dependent on Neuropilin-1. Can. Res. 67:10309–10316.
33. Gomez Toledo, A., J. Nilsson, F. Noborn, C. Sihlbom, and G. Larson. 2015. Positive Mode LC-MS/MS analysis of chondroitin sulfate modified glycopeptides derived from light and heavy chains of the human inter-alpha-trypsin inhibitor complex. Mol. Cell Proteomics mcp.M115.051136.
34. Pan, S., R. Chen, R. E. Brand, S. Hawley, Y. Tamura, P. R. Gafken, et al. 2012. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J. Proteome Res. 11:1937–1948.
35. Paulo, J. A., L. S. Lee, P. A. Banks, H. Steen, and D. L. Conwell. 2012. Proteomic analysis of formalin-fixed paraffin-embedded pancreatic tissue using liquid chromatography tandem mass spectrometry (LC-MS/MS). Pancreas 41:175–185.
36. Kuo, K. K., C. J. Kuo, C. Y. Chiu, S. S. Liang, C. H. Huang, S. W. Chi, et al. 2016. Quantitative proteomic analysis of differentially expressed protein profiles involved in pancreatic ductal adenocarcinoma. Pancreas 45:71–83.
37. Chen, R., S. Pan, K. Cooke, K. W. Moyes, M. P. Bronner, D. R. Goodlett, et al. 2007. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34:70–79.
38. Zhao, J., T. H. Patwa, W. Qiu, K. Shedden, R. Hinderer, D. E. Misek, et al. 2007. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J. Proteome Res. 6:1864–1874.
39. Nie, S., A. Lo, J. Wu, J. Zhu, Z. Tan, D. M. Simeone, et al. 2014. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J. Proteome Res. 13:1873–1884.
40. Ueda, C., Y. Hirohata, Y. Kihara, H. Nakamura, S. Abe, K. Akahane, et al. 2001. Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J. Gastroenterol. 36:848–850.
41. Kakkar, A. K., N. R. Lemoine, M. F. Scully, S. Tebbutt, and R. C. N. Williamson. 1995. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br. J. Surg. 82:1101–1104.
42. Zwicker, J. I., B. C. Furie, and B. Furie. 2007. Cancer-associated thrombosis. Crit. Rev. Oncol. Hematol. 62:126–136.
43. Haas, S. L., R. Jesnowski, M. Steiner, F. Hummel, J. Ringel, C. Burstein, et al. 2006. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J. Gastroenterol. 12:4843–4849.